Moderna, the biotech company behind one of the original mRNA COVID-19 vaccines, is undergoing an AI-powered workplace ...

The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the ...

Learn more about whether Kymera Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Moderna’s Chief People & Digital Officer, Tracey Franklin, has become the latest high-profile executive to reveal how agentic ...

MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic Diabetes as its chief marketing ...

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting ...

Moderna reiterated its full-year 2025 product sales forecast of $1.5 billion to $2.5 billion, with most expected in the ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% ...

"In the first quarter, we continued to execute with financial discipline, significantly reducing our operating expenses, and further prioritized our investments in oncology," said Stéphane Bancel, ...